MIRM
HealthcareMirum Pharmaceuticals, Inc. · Biotechnology · $5B
What is Mirum Pharmaceuticals, Inc.?
Mirum Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan liver diseases. Incorporated in 2018 and headquartered in Foster City, California, Mirum targets conditions with limited treatment options.
Mirum generates revenue primarily through LIVMARLI, an oral therapy targeting rare cholestatic liver diseases including progressive familial intrahepatic cholestasis, Alagille syndrome, and biliary atresia. The company also advances Volixibat, a pipeline candidate being studied for intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Its business model centers on orphan-disease designation advantages, which can provide regulatory incentives and reduced competition in niche patient populations.
Mirum Pharmaceuticals was incorporated in 2018 and is headquartered in Foster City, California.
- LIVMARLI — oral therapy for rare cholestatic liver diseases
- Volixibat — pipeline drug for cholestasis of pregnancy and PSC
- Rare and orphan disease drug development platform
- Commercialization capabilities for specialty biopharmaceuticals
Is MIRM a Good Stock to Buy?
UQS Score rates MIRM as Below Average overall, reflecting a mixed profile across its five evaluation pillars.
The Growth pillar stands out as the clearest bright spot — Mirum is expanding its commercial footprint in rare liver diseases at a pace that ranks among the stronger performers in the healthcare sector. The Risk and Moat pillars both register as Neutral, suggesting the company is neither unusually fragile nor particularly entrenched relative to peers.
The Quality pillar scores as Weak, pointing to underlying profitability and financial-health challenges typical of early-commercial-stage biotechs. Valuation is rated Elevated, meaning the market is pricing in considerable future success.
See the exact pillar breakdown and full financial metrics by signing up for a UQS Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does MIRM pay dividends?
No — Mirum Pharmaceuticals, Inc. does not currently pay a dividend.
Mirum Pharmaceuticals does not currently pay a dividend. As an early-commercial-stage rare-disease biotech, the company directs available capital toward clinical development, regulatory activities, and commercial expansion rather than shareholder distributions. Income-focused investors should factor this into their assessment.
When does MIRM report earnings?
Mirum Pharmaceuticals reports earnings on a quarterly cadence, consistent with US-listed biopharmaceutical companies.
Quarterly results have reflected the company's transition from a development-stage entity to a commercial-stage business, with revenue growth driven by LIVMARLI adoption. Profitability remains a work in progress, as is typical for rare-disease biotechs building out their commercial infrastructure.
For the most recent quarter's results and guidance, visit Mirum Pharmaceuticals' investor relations page directly.
MIRM Price History
+464.3% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Mirum Pharmaceuticals, Inc.?
Based on Mirum Pharmaceuticals, Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
MIRM Long-term Outlook
Mirum's Strong Growth pillar suggests the business is expanding at a meaningful rate relative to its healthcare peers, driven by increasing adoption of LIVMARLI across approved indications. However, the Elevated Valuation pillar indicates the current share price already reflects a great deal of that anticipated growth, leaving limited room for execution shortfalls. The Neutral Risk profile suggests the company faces a balanced — though real — set of operational and clinical uncertainties.
Growth drivers
- Expanding LIVMARLI adoption across multiple rare cholestatic liver disease indications
- Potential label expansions and new approvals for pipeline candidate Volixibat
- Orphan-disease regulatory incentives supporting commercial exclusivity
Key risks
- Elevated valuation leaves little margin for clinical or commercial disappointment
- Weak Quality pillar reflects ongoing profitability pressures and cash consumption
- Pipeline execution risk inherent in rare-disease drug development
MIRM vs Peers
Mirum operates in a competitive rare-disease and specialty biopharmaceutical space alongside several focused peers.
Corcept focuses on cortisol modulation therapies and has a more established commercial product generating consistent revenue, contrasting with Mirum's earlier-stage commercial profile.
Terns is a clinical-stage company targeting metabolic and liver diseases, competing in overlapping therapeutic areas but without Mirum's currently marketed product.
Xenon concentrates on ion-channel neurology therapies, sharing the rare-disease focus but operating in a distinct therapeutic category from Mirum's liver-disease franchise.
Frequently Asked Questions
What does Mirum Pharmaceuticals do?
Mirum Pharmaceuticals develops and commercializes therapies for rare and orphan liver diseases. Its lead product, LIVMARLI, treats progressive familial intrahepatic cholestasis, Alagille syndrome, and biliary atresia. The company also has a pipeline candidate, Volixibat, targeting additional cholestatic conditions.
Does MIRM pay dividends?
No, Mirum Pharmaceuticals does not pay a dividend. The company reinvests available capital into clinical development and commercial expansion of its rare-disease portfolio, which is standard practice for early-commercial-stage biotechs.
When does MIRM report earnings?
Mirum Pharmaceuticals reports on a quarterly cadence, as is typical for US-listed companies. For exact upcoming report dates, check the company's investor relations page or your brokerage's earnings calendar.
Is MIRM a good stock to buy?
UQS Score rates MIRM as Below Average overall. The Growth pillar is Strong, but the Quality pillar is Weak and Valuation is Elevated — meaning investors are paying a premium for future growth that has yet to fully materialize. The full pillar breakdown is available to UQS Pro members.
Is MIRM overvalued?
The UQS Valuation pillar for MIRM is rated Elevated, suggesting the stock is priced above what fundamentals alone might justify at this stage. This is common for rare-disease biotechs with strong growth trajectories but limited current profitability.
How does MIRM compare to its competitors?
Mirum differentiates itself through a commercially approved rare liver-disease product — LIVMARLI — while some peers remain in earlier clinical stages. However, competitors like Corcept Therapeutics have more established profitability profiles. See the competitor section above for a fuller comparison.
What is MIRM's market cap bracket?
Mirum Pharmaceuticals is classified as a mid-cap company. This places it in a range that typically reflects an established commercial presence but with meaningful room for growth relative to large- or mega-cap pharmaceutical peers.
Who founded Mirum Pharmaceuticals?
Mirum Pharmaceuticals was incorporated in 2018. Founding and leadership details are publicly available through the company's official filings and investor relations materials for those seeking a full history.
Is MIRM a long-term quality investment?
As a long-term quality indicator, the UQS Score rates MIRM as Below Average. The Strong Growth pillar is encouraging, but the Weak Quality and Elevated Valuation pillars suggest investors should weigh execution risk carefully before treating this as a core long-term holding.
What is the main competitive advantage of Mirum Pharmaceuticals?
Mirum's primary edge lies in its focus on orphan diseases, which can provide regulatory incentives, smaller competitive fields, and pricing power. LIVMARLI's approval across multiple rare cholestatic indications gives the company a commercial foothold that pure pipeline-stage peers lack.
What sector does MIRM belong to?
Mirum Pharmaceuticals operates in the Healthcare sector, specifically within the biopharmaceutical industry. Its niche focus on rare and orphan liver diseases places it in the specialty pharma and rare-disease subsegment of healthcare.
Is MIRM a growth stock or value stock?
Based on UQS pillar labels, MIRM leans firmly toward growth — the Growth pillar is rated Strong while Valuation is Elevated, meaning the market prices in significant future expansion. It does not exhibit the characteristics typically associated with value-oriented investments.
Unlock Full MIRM Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the exact UQS Score and all five pillar scores
- ✓Access complete financial metrics and trend data
- ✓Compare MIRM against sector peers side by side
- ✓See the full risk and valuation breakdown
- ✓Get the complete analyst-style quality report
- ✓Track score changes as new data is released
Pro Analysis
MIRM — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 20, 2026 | 42.2 | 16.7 | 41.0 | 100.0 | 52.1 | 0.0 | -0.1 |
| May 9, 2026 | 42.3 | 16.7 | 41.0 | 100.0 | 52.5 | 0.0 | +0.3 |
| May 4, 2026 | 42.0 | 19.0 | 41.0 | 100.0 | 46.9 | 0.1 | 0.0 |
| Apr 19, 2026 | 42.0 | 19.0 | 41.0 | 100.0 | 46.9 | 0.0 | 0.0 |
| Apr 11, 2026 | 42.0 | 19.1 | 41.0 | 100.0 | 46.9 | 0.0 | 0.0 |
| Apr 7, 2026 | 42.0 | 19.0 | 41.0 | 100.0 | 46.9 | 0.0 | -0.1 |
| Apr 2, 2026 | 42.1 | 19.1 | 41.0 | 100.0 | 46.9 | 0.0 | — |
MIRM — Pillar Breakdown
Quality
— 16.7/100 (25%)Mirum Pharmaceuticals, Inc. currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 100.0/100 (20%)Mirum Pharmaceuticals, Inc. is growing rapidly with strong revenue and earnings expansion.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Risk
— 52.1/100 (15%)Mirum Pharmaceuticals, Inc. has some risk factors including moderate leverage or solvency concerns.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 0.0/100 (15%)Mirum Pharmaceuticals, Inc. appears expensively valued relative to its fundamentals and growth prospects.
How many years of FCF the market cap represents.
Moat
— 41/100 (25%)Mirum Pharmaceuticals, Inc. possesses some competitive advantages but faces meaningful competition. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for MIRM.
Score Composition
Financial Data
More Stock Analysis
How is the MIRM UQS Score Calculated?
The UQS (Unified Quality Score) for Mirum Pharmaceuticals, Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Mirum Pharmaceuticals, Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Mirum Pharmaceuticals, Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.